Sutro Biopharma (STRO) Competitors $0.58 -0.02 (-3.12%) As of 02:26 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STRO vs. SLRN, CADL, SLDB, ACB, PVLA, OLMA, CMPX, IMMP, DRUG, and FHTXShould you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Acelyrin (SLRN), Candel Therapeutics (CADL), Solid Biosciences (SLDB), Aurora Cannabis (ACB), Palvella Therapeutics (PVLA), Olema Pharmaceuticals (OLMA), Compass Therapeutics (CMPX), Immutep (IMMP), Bright Minds Biosciences (DRUG), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry. Sutro Biopharma vs. Acelyrin Candel Therapeutics Solid Biosciences Aurora Cannabis Palvella Therapeutics Olema Pharmaceuticals Compass Therapeutics Immutep Bright Minds Biosciences Foghorn Therapeutics Acelyrin (NASDAQ:SLRN) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Which has more risk and volatility, SLRN or STRO? Acelyrin has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Is SLRN or STRO more profitable? Acelyrin has a net margin of 0.00% compared to Sutro Biopharma's net margin of -77.01%. Acelyrin's return on equity of -44.12% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets AcelyrinN/A -44.12% -39.02% Sutro Biopharma -77.01%-101.89%-28.69% Do analysts prefer SLRN or STRO? Acelyrin currently has a consensus price target of $9.60, suggesting a potential upside of 334.39%. Sutro Biopharma has a consensus price target of $6.63, suggesting a potential upside of 1,045.60%. Given Sutro Biopharma's higher probable upside, analysts plainly believe Sutro Biopharma is more favorable than Acelyrin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acelyrin 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Sutro Biopharma 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22 Which has preferable earnings & valuation, SLRN or STRO? Sutro Biopharma has higher revenue and earnings than Acelyrin. Acelyrin is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcelyrinN/AN/A-$381.64M-$2.50-0.88Sutro Biopharma$62.04M0.77-$106.79M-$3.02-0.19 Does the MarketBeat Community favor SLRN or STRO? Sutro Biopharma received 116 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 64.08% of users gave Sutro Biopharma an outperform vote while only 55.17% of users gave Acelyrin an outperform vote. CompanyUnderperformOutperformAcelyrinOutperform Votes1655.17% Underperform Votes1344.83% Sutro BiopharmaOutperform Votes13264.08% Underperform Votes7435.92% Do institutionals & insiders hold more shares of SLRN or STRO? 87.3% of Acelyrin shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 13.6% of Acelyrin shares are held by company insiders. Comparatively, 5.9% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor SLRN or STRO? In the previous week, Acelyrin had 3 more articles in the media than Sutro Biopharma. MarketBeat recorded 4 mentions for Acelyrin and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.87 beat Acelyrin's score of 1.53 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Acelyrin Very Positive Sutro Biopharma Very Positive SummarySutro Biopharma beats Acelyrin on 11 of the 17 factors compared between the two stocks. Remove Ads Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRO vs. The Competition Export to ExcelMetricSutro BiopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.69M$2.89B$5.32B$7.56BDividend YieldN/A1.91%5.11%4.33%P/E Ratio-0.3630.8821.7717.81Price / Sales0.77435.82378.2693.59Price / CashN/A168.6838.1534.64Price / Book0.243.476.443.99Net Income-$106.79M-$72.06M$3.20B$247.23M7 Day Performance-8.94%8.57%6.42%7.24%1 Month Performance-28.61%-17.48%-8.66%-6.26%1 Year Performance-86.03%-29.58%10.27%-0.18% Sutro Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STROSutro Biopharma4.2986 of 5 stars$0.58-3.1%$6.63+1,045.6%-85.6%$47.69M$62.04M-0.36240Positive NewsSLRNAcelyrin3.5745 of 5 stars$2.31-4.9%$9.60+315.6%-59.4%$232.64MN/A-0.94135Short Interest ↓News CoveragePositive NewsCADLCandel Therapeutics2.2768 of 5 stars$4.84+0.4%$21.00+333.9%-22.4%$228.62M$120,000.00-2.8060Short Interest ↑SLDBSolid Biosciences3.3921 of 5 stars$2.94-5.8%$15.67+432.9%-73.9%$227.83M$8.09M-0.97100Positive NewsGap UpACBAurora Cannabis0.535 of 5 stars$4.05+0.7%N/A-35.6%$227.67M$320.81M81.021,340PVLAPalvella Therapeutics3.6173 of 5 stars$20.07-16.3%$43.50+116.7%N/A$221.15M$42.81M-1.66N/AAnalyst RevisionOLMAOlema Pharmaceuticals2.9218 of 5 stars$3.18-2.2%$27.67+770.0%-62.6%$217.30MN/A-1.4570Short Interest ↓Positive NewsCMPXCompass Therapeutics3.4032 of 5 stars$1.57+7.5%$13.38+751.9%+6.2%$217.10M$850,000.00-4.2420Short Interest ↑Gap DownIMMPImmutep1.6279 of 5 stars$1.42-5.3%$8.50+498.6%-40.2%$206.69M$5.14M0.002,021Gap DownDRUGBright Minds Biosciences3.2112 of 5 stars$29.25-8.7%$84.33+188.3%+2,478.7%$206.04MN/A-172.05N/ANews CoveragePositive NewsFHTXFoghorn Therapeutics2.5509 of 5 stars$3.68+7.0%$13.17+257.8%-51.6%$204.65M$22.60M-1.92120News CoveragePositive News Remove Ads Related Companies and Tools Related Companies Acelyrin Alternatives Candel Therapeutics Alternatives Solid Biosciences Alternatives Aurora Cannabis Alternatives Palvella Therapeutics Alternatives Olema Pharmaceuticals Alternatives Compass Therapeutics Alternatives Immutep Alternatives Bright Minds Biosciences Alternatives Foghorn Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STRO) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredFmr. Presidential Advisor’s Urgent Warning: “Exit Tech Now!”A former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
